Begins Coverage on Prime Medicine (NYSE:PRME) assumed coverage on shares of Prime Medicine (NYSE:PRMEGet Rating) in a report published on Thursday morning. The firm issued a sell rating on the stock.

Prime Medicine Stock Performance

Prime Medicine stock opened at $12.29 on Thursday. The stock has a 50-day simple moving average of $17.06. Prime Medicine has a 52 week low of $12.29 and a 52 week high of $21.73.

Prime Medicine Company Profile

(Get Rating)

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Read More

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with's FREE daily email newsletter.